dwj1622
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 5, 2025 (NCT07260851)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Mechanism of action
- Dopamine D3 receptorMODULATOR
DRD3 modulator
Serotonin receptor 2a and 2b (5HT2A and 5HT2B) modulator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07267221 | Phase 1 | Dec 1, 2025 | Daewoong Pharmaceutical Co. LTD. |
| NCT07260851 | Phase 1 | Nov 5, 2025 | Daewoong Pharmaceutical Co. LTD. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Daewoong Pharmaceutical Co. LTD. | For profit | 2 | 2 | 1 | 2025 |
1 organizations
Page 1 / 1